The body’s innate and adaptive immune system’s ability to recognize and attack tumor cells is a powerful tool in oncology drug discovery research. However, the complex biology of numerous analytes and cytokines released by the tumor allows for the development of an immune-suppressed and immune-evasive microenvironment, which permits tumor cell proliferation, vascularization, and ultimately metastasis to distal sites in the body.
At Charles River, we have developed a platform to profile your new agent in in vitro immuno-oncology assays that mimic this complex biology. Using state-of-the-art technology and industry-recognized protocols, we can confirm the activation of immune cell populations, help elucidate the mechanism of action, and, in co-culture environments, confirm clustering of T cells, and visualize and quantitate T-cell mediated cancer cell killing. These assays have been validated with clinically relevant standard of care molecules in immuno-oncology and correlated their effects with changes in cytokine and chemokine levels as well as functional recognition and enhanced tumor cell killing.
Our platform is focused to improve translational relevance to support the progression of your compound into in vivo PD studies, confirming immune cell activation, immune cell population changes in the tumor, and cell surface marker changes of immune activation. Your compound can be translated into our in vivo models, including fully validated syngeneic models or humanized mouse models engrafted with human PBMC or CD34+ cells, inoculated with tumors from our PDX collection.
Our robust, translatable platform of in vitro and in vivo assays, coupled with our extensive immunology and oncology expertise, delivers a comprehensive data package around your compounds, which supports the progression from pre-clinical development to IND submission. Start your biologic or small molecule on the road to discovery with our optimized off-the-shelf T cell assays.